NANEMIAR project participated at the prestigious European Hematology Association (EHA) Annual Congress, held from June 12 to 15, 2025, in Milan, Italy.

During the event, Dr. Laura Braud of the CNRS, presented the latest work from the NANEMIAR project with a scientific poster “A new Method for Analyzing Bone Marrow Cell Populations by Spectral Flow Cytometry”. This work was presented during the scientific sessions dedicated to rare hematological diseases and stood out for its innovative approach and the relevance of its contributions to the diagnosis and treatment of congenital anemias.

Manuel Bernabé was present from FFIS-IMIB in order to take advantage of the opportunities to learn and create synergies with other professionals in the field that this congress offers.

The NANEMIAR (Nanomedicine Approach to Normalize Erytrocyte Maturation in Congenital Anemia by mRNA) project focuses on the development of new personalized therapeutic strategies for patients with hereditary anemias, a group of pathologies that, although rare, present high clinical complexity and a significant impact on the quality of life of those who suffer from them. NANEMIAR seeks to advance precision medicine that allows for more effective, safer, and more tailored treatments to each patient's genetic profile. 

We remain steadfast in our commitment to transformative, collaborative, and excellent research that contributes to the future of hematology and the improvement of medical care for rare diseases.

Cathegory: Other related events

Dr. Laura Braud of the CNRS (on the right)

Laura Braud of the CNRS (on the right)

Manuel Bernabé of the FFIS-IMIB (on the left)